Abstract
Mycosis is still one of the most problematic illness worldwide in hospitals and homes etc. Many antifungal drugs have been developed recently in the world. Voriconazole, posaconazole and ravuconazole (three new azoles), caspofungin, anidulafungin and micafungin (three new echinocandins), mycograb of monoclonal antifungal antibody, butenafin hydrochloride (one of the benzylamine compounds), terbinafine (an allylamine antifungal agent), and amphotericin B (one of the polyene groups) are representative antifungal drugs used worldwide. Recently, new antifungal drugs such as polyene SPE-843, acrylamide T-2307, ambruticin analog, isavuconazole, icofungipen, and pyridobenzimidazole 75-4590 have also been introduced. In this report, I discuss the introduction of several recently developed antifungal drugs, and also describe the mechanism of action of antifungal drugs and the combination effect between antifungal drugs. Finally, I emphasize in this report that both combination therapy and the development of new antifungal drugs are to be expected in the near future.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Burnie J, Matthews R (2003) The role of antibodies against hsp 90 in the treatment of fungal infections. Drug News Perspect 16:205–210
Burnie J, Matthews R (2004) Genetically recombinant antibodies: new therapeutics against candidiasis. Expert Opin Biol Ther 4:233–241
Chen HH, Liushih RN, Hsieh WC (1982) Combined in vitro activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans and Candida albicans. Chin J Microbiol Immunol 15:106–112
Develoux M (2001) Griseofulvin. Ann Dermatol Venereol 128:1317–1325
Espinel-Ingroff A (2009) Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005–2009). Rev Iberoam Micol 26:15–22
Hughes CE, Peterson LR, Beggs WH, Gerding DN (1986) Ketoconazole and flucytosine alone and in combination against Candida spp. in a neutropenic site in rabbits. J Antimicrob Chemother 18:65–72
Kaken Pharmaceutical Co., Ltd. Press release, JAPAN 21 April, 1999
Loo Daniel S (2006) Systemic antifungal agents: an update of established and new therapies. Adv Dermatol 22:101–124
Martin E, Maier F, Bhakdi S (1994) Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob Agents Chemother 38:1331–1338
McClellan KJ, Wiseman LR, Markham A (1999) Terbinafine. An update of its use in superficial mycoses. Drugs 58:179–202
Michele MI (2006) Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm 63:1693–1703
Milefchik E, Leal MA, Haubrich R, Bozzette SA, Tilles JG, Leedom JM, McCutchan JA, Larsen RA (2008) Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 46:393–395
Mori T (2008) Medical history and progress in infectious diseases, especially systemic fungal infections in Japan (in Japanese). Jpn J Med Mycol 49:5–17
Nair AB, Sammeta SM, Vaka SR, Narasimha Murthy S (2009) A study on the effect of inorganic salts in transungual drug delivery of terbinafine. J Pharm Pharmacol 61:431–437
Nguyen MH, Barchiesi F, McGough DA, Yu VL, Rinaldi MG (1995) In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother 39:1691–1695
Nishi I, Sunada A, Toyokawa M, Asari S, Iwatani Y (2009) In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B and flucytosine against clinical isolates of Candida species. J Infect Chemother 15:1–5
Pachl J, Svoboda P, Jacobs F, Vandewoude K, van der Hoven B, Spronk P, Masterson G (2006) A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of Heat Shock Protein 90 in patients with invasive candidiasis. Clin Infect Dis 42:1404–1413
Polak A (1978) Synergism of polyene antibiotics with 5-fluorocytosine. Chemotherapy 24:2–16
Samaranayake YH, Cheung BP, Parahitiyawa N, Seneviratne CJ, Yau JY, Yeung KW, Samaranayake LP (2009) Synergistic activity of lysozyme and antifungal agents against Candida albicans biofilms on denture acrylic surfaces. Arch Oral Biol 54:115–126
Singal A (2008) Butenafine and superficial mycoses: current status. Expert Opin Drug Metab Toxicol 4:999–1005
Vermes A, Guchelaar HJ, Dankert J (2000) Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 46:171–179
Vital RG, Afeltra J, de Hoog GS, Rijs AJ, Verweij PE (2003) In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera. J Antimicrob Chemother 51:1297–1300
Vladimir K (2007) Antifungal drug discovery, six new molecules patented after 10 years of feast: why do we need new patented drugs apart from new strategies? Recent Pat Antiinfect Drug Discov 2:182–187
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Sakagami, Y. (2010). Antifungal Drugs Mode of Action and Recent Development. In: Ahmad, I., Owais, M., Shahid, M., Aqil, F. (eds) Combating Fungal Infections. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12173-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-12173-9_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-12172-2
Online ISBN: 978-3-642-12173-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)